Proposition 2 definition

Proposition 2. For some initial capital endowments, North is better off (and the South is worse off) under bargaining over trade and aid than under free-trade.
Sample 1Sample 2
Proposition 2. Assuming that P 1, a lower bound on the secret-key agreement capacity is capacity is given by, 2 √
Sample 1Sample 2
Proposition 2. With banks’ efforts, the incentive coefficient increases. The difference of incentive coefficient in two cases is as follows: (κ +θ )2 κ 2 1 1 Δβ = β ** − β * = − = − > 0 (κ +θ )2 + λρσ 2 κ 2 + λρσ 2 λρσ 2 1+ (κ +θ )2 λρσ 2 1+ κ 2 From (17), we see that banks will give B2B platforms more incentive rewards under banks’ effort.
Sample 1

Examples of Proposition 2 in a sentence

  • However, Proposition 2 also mandates draws on the PSSSA in any fiscal year in which the estimated minimum funding guarantee is less than the prior year’s funding level, as adjusted for ADA growth and cost of living.

  • Proposition 2 caps the size of the PSSSA at 10% of the estimated minimum guarantee in any fiscal year, and any excess funds must be paid to K-14 school districts.

  • The Commonwealth of Massachusetts electorate in November, 1980, passed legislation known as Proposition 2 1/2, in order to limit the amount of revenue to be raised by taxation.

  • The Town must establish its property tax rate each year so that the property tax rate levy will comply with the limits established by Proposition 2 1/2, as amended, and also equal the sum of (a) the aggregate of all annual appropriations for expenditures, plus (b) provision for prior year deficits, if any, less (c) the aggregate of all non-property tax revenues estimated to be received, including available funds.

  • The City must establish its property tax rate each year so that the property tax rate levy will comply with the limits established by Proposition 2 1/2, as amended, and also equal the sum of (a) the aggregate of all annual appropriations for expenditures, plus (b) provision for prior year deficits, if any, less (c) the aggregate of all non-property tax revenues estimated to be received, including available funds.

  • Proposition 2 caps the size of the PSSSA at 10% of the estimated minimum funding guarantee in any fiscal year, and any excess funds must be paid to K-14 school districts.

  • This corresponds to the linear price equilibrium described in Proposition 2.

  • First, from Proposition 2, the post-trade exposure function, g(ω), is Liptchitz with a coefficient that does not depend on n(ω).

  • Using the result from Proposition 2, we know that in equilibrium, the minimum level of switching costs is RJ.

  • Proposition 2 shows that it is important to take into account the budget constraint of the public sector.


More Definitions of Proposition 2

Proposition 2. Assuming that P 1, a lower bound on the secret-key agreement capacity is capacity is given by, √ 1 ∆(P + Q + 2ρ√PQ) contrast the common reconstruction sequence in this problem is an intermediate step used to generate a common secret key. R− = log 1 + P + Q + 1 + ∆ + 2ρ , (12) PQ While we do not have a matching upper bound to Theorem 1 the following result provides an upper bound to the secret-key capacity that is amenable to numerical evaluation.
Sample 1
Proposition 2. For European put options, its ∆ hedge is given by ∆ = N (−d1).
Sample 1
Proposition 2. Shall Section 4 of Article I of the Charter be amended to provide that when the City approves a subdivision plat, the plat shall show all public improvements that are being dedicated to the City and the City’s acceptance of the public improvements will not occur until the City does so by actual appropriation, entry, use, or improvement of the dedicated property? □ For □ Against In the event that Proposition 2 is approved by the voters on November 4, 2014, Section 4 of Article I of the Pampa Charter shall thereafter read as follows:
Sample 1
Proposition 2. If society aims to punish the guilty, deter harmful acts but not chill benign ones, and avoid erroneous verdicts, then discretion is optimal if and only if (6’) ≥ (5’). If the model is applied to a civil dispute between two private parties, the costs of a “wrongful conviction” and “false acquittal” need reinterpretation. A transfer of wealth from one party to the other is not necessarily a welfare cost at all.
Sample 1

Related to Proposition 2

  • Ballot proposition means a question, issue, or proposal that is submitted to voters

  • Phase III means Phase I (or Phase I/II), Phase II (or Phase II/III) and Phase III clinical trials, respectively, in each case as prescribed by applicable FDA IND Regulations, or any corresponding foreign statutes, rules or regulations.

  • Phase 1 means the first implementation phase of this section, beginning June 1, 2018 and ending May 31, 2022.

  • Improvement completion assurance means a surety bond, letter of credit,

  • Phase 2 means the second implementation phase of this section, beginning June 1, 2022 and continuing thereafter.

  • Phase 3 means the period commencing on the day after the Phase 2 implementation date and ending on the Phase 3 implementation date (as defined below).

  • Completion Deadline means the date by which the Arrangement is to be completed, which date shall be April 30, 2014 or such later date as may be agreed to in writing by the Parties;

  • Proposal means the Technical Proposal and the Financial Proposal.

  • Phase I means the first part of the tuition incentive assistance program defined as the academic period of 80 semester or 120 term credits, or less, leading to an associate degree or certificate.

  • Project Proposal is the final and written description of the Project as described in Exhibit A, to be undertaken by Sub-recipient for which the Project Funds is granted and performance is required and monitored pursuant to this PFA.

  • conformity assessment means the process demonstrating whether the requirements of this Regulation relating to a device have been fulfilled;

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase II means the second part of the tuition incentive assistance program which provides assistance in the third and fourth year of 4-year degree programs.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Project Proponent means the individual or organization that has overall control and responsibility for the Project, or an individual or organization that together with others, each of which is also a Project Proponent, has overall control or responsibility for the Project. The entity(s) that can demonstrate Project Ownership in respect of the Project. For the avoidance of doubt where an individual executes this Representation in their capacity as an authorized office holder of the company who is the Project Proponent, this Representation is made by the company, not the authorized office holder;

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Study Completion means the database for the Study has been locked and all Essential Documents have been provided to the Sponsor, including a copy of the letter from the Reviewing HREC acknowledging receipt of the final report and/or closure letter from the Principal Investigator.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • project completion period means the period of sixty (60) months commencing from and expiring on for the construction and obtaining of Temporary Occupation Permit or Permits for the whole of the Development as provided in clause 3.3;

  • Cluster development means a contiguous cluster or

  • ESA means the Federal Endangered Species Act of 1973, as amended (16 U.S.C. §§ 1531-1544) and all rules, regulations, and guidelines promulgated pursuant to that Act.

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Integration Proponent means in relation to an Integration Agreement, “the Company” or “the Joint Venturers” as the case may be as defined in, and for the purpose of, that Integration Agreement;

  • Treatability study means a study in which a hazardous waste is subjected to a treatment process to determine: (1) Whether the waste is amenable to the treatment process, (2) what pretreatment (if any) is required, (3) the optimal process conditions needed to achieve the desired treatment, (4) the efficiency of a treatment process for a specific waste or wastes, or (5) the characteristics and volumes of residuals from a particular treatment process. Also included in this definition for the purpose of the § 261.4 (e) and (f) exemptions are liner compatibility, corrosion, and other material compatibility studies and toxicological and health effects studies. A “treatability study” is not a means to commercially treat or dispose of hazardous waste.